Your browser is no longer supported. Please, upgrade your browser.
GSK GlaxoSmithKline plc daily Stock Chart
GlaxoSmithKline plc
Index- P/E43.69 EPS (ttm)0.89 Insider Own0.20% Shs Outstand2.45B Perf Week-0.10%
Market Cap94.79B Forward P/E13.54 EPS next Y2.86 Insider Trans0.00% Shs Float2.44B Perf Month-9.40%
Income2.17B PEG3.52 EPS next Q0.82 Inst Own9.60% Short Float0.17% Perf Quarter-11.12%
Sales37.68B P/S2.52 EPS this Y-89.20% Inst Trans1.38% Short Ratio1.47 Perf Half Y-6.27%
Book/sh0.91 P/B42.58 EPS next Y0.32% ROA2.90% Target Price48.00 Perf Year-12.90%
Cash/sh2.44 P/C15.89 EPS next 5Y12.40% ROE188.80% 52W Range37.20 - 44.58 Perf YTD0.62%
Dividend1.99 P/FCF45.49 EPS past 5Y-28.90% ROI8.60% 52W High-13.08% Beta1.02
Dividend %5.14% Quick Ratio0.60 Sales past 5Y0.40% Gross Margin68.40% 52W Low4.17% ATR0.44
Employees99827 Current Ratio0.90 Sales Q/Q18.50% Oper. Margin12.40% RSI (14)23.89 Volatility0.71% 0.89%
OptionableYes Debt/Eq10.70 EPS Q/Q271.90% Profit Margin5.80% Rel Volume0.89 Prev Close39.05
ShortableYes LT Debt/Eq8.52 EarningsJul 26 Payout232.70% Avg Volume2.77M Price38.75
Recom2.00 SMA20-3.90% SMA50-7.75% SMA200-5.19% Volume2,460,007 Change-0.77%
Jul-05-17Downgrade Citigroup Buy → Neutral
May-26-17Upgrade Berenberg Hold → Buy
Apr-05-17Upgrade Exane BNP Paribas Underperform → Neutral
Mar-09-17Initiated Liberum Buy
Mar-09-17Initiated Kepler Reduce
Oct-20-16Initiated Investec Buy
Sep-23-16Initiated Piper Jaffray Overweight
Jul-14-16Upgrade Jefferies Hold → Buy
Mar-30-16Upgrade Citigroup Neutral → Buy
Feb-26-16Initiated Cantor Fitzgerald Hold
Dec-09-15Upgrade BofA/Merrill Neutral → Buy
Dec-07-15Reiterated Argus Buy $52 → $48
Oct-20-15Upgrade Credit Suisse Underperform → Neutral
Sep-15-15Upgrade Exane BNP Paribas Underperform → Neutral
Sep-08-15Upgrade BofA/Merrill Underperform → Neutral
Jun-26-15Upgrade Liberum Sell → Hold
Jun-04-15Downgrade Morgan Stanley Overweight → Equal-Weight
May-20-15Resumed Citigroup Neutral
Apr-15-15Initiated Societe Generale Sell
Feb-19-15Reiterated Argus Buy $55 → $52
Aug-18-17 04:18PM  Mylan Finalizes Settlement Agreement with DOJ for $465M Zacks
Aug-17-17 11:32AM  [$$] The questionable strategy of a pharmaceuticals CEO Financial Times
Aug-15-17 04:55AM  Shire Gains as it Seeks European Approval For Dry Eye Treatment
Aug-14-17 01:39PM  [$$] The key to innovation is balancing risk and rigour Financial Times
10:14AM  What Happened In Biotech Last Week?
08:32AM  Ionis Pharmaceuticals Retains Rights to Inotersen, Stock Up Zacks
Aug-13-17 12:49PM  Stocks That Fell to 3-Year Lows in the Week of August 11
Aug-12-17 02:51PM  Where Does Zika Virus Vaccine Research Stand Now? Benzinga
Aug-11-17 05:36PM  ETFs with exposure to GlaxoSmithKline Plc : August 11, 2017 Capital Cube
04:07PM  Ionis Pharmaceuticals Inc: Growing Royalties, an Advancing Pipeline, and Getting Back Rights to Some Drugs Motley Fool
10:01AM  Biotech movers: Ionis Drops After GSK Bows Out of Partnership
Aug-10-17 01:39PM  Former GSK exec resigns from Intellia board due to 'conflict' American City Business Journals
12:30PM  UK fraud office expects decision on GSK, Rolls-Royce cases next year Reuters
12:16PM  UK fraud office expects decision on GSK, Rolls-Royce cases next year Reuters
09:15AM  3 High-Yield Healthcare Stocks Motley Fool
01:54AM  European Stocks Set for Mixed Open as Global Markets Stabilize
Aug-09-17 07:03PM  [$$] Blockbuster drugs depend on marketing, not design Financial Times
04:11PM  Mexico watchdog finds big pharma faces no competition on some drugs Reuters
Aug-08-17 06:17AM  Drugmakers' hopes for gene therapy rise despite tiny sales in Europe Reuters
Aug-07-17 04:09PM  Epizyme (EPZM) Incurs Narrower-than-Expected Loss in Q2 Zacks
Aug-06-17 10:23AM  [$$] GSK chief vows to stop 'drifting off in hobbyland' with R&D Financial Times
10:15AM  [$$] GSK chief says her lack of 'baggage' in pharma is an advantage Financial Times
Aug-04-17 06:04PM  Analysts say a United Therapeutics sale is premature American City Business Journals
05:08PM  United Therapeutics Corporation (UTHR) Shares Soar on Takeover Talk InvestorPlace
04:19PM  Emergent (EBS) Q2 Earnings Miss Estimates, Revenues Rise Y/Y Zacks
12:15PM  Gilead Could Be Making An Acquisition But It's Not What You Think Investor's Business Daily
10:12AM  Agenus (AGEN) Q2 Loss Narrower Than Expected, Revenues Lag Zacks
08:47AM  United Therapeutics Corp. stock surges 9% on report of possible bids for company MarketWatch
Aug-03-17 07:36AM  GlaxoSmithKlines Valuations after Its 2Q17 Earnings Market Realist
Aug-02-17 04:28PM  U.S. FDA panel votes against approval of J&J arthritis drug Reuters
10:37AM  GSKs 2Q17 Earnings: Consumer Healthcare Market Realist
09:07AM  GlaxoSmithKlines 2Q17 Earnings: Vaccines Business Market Realist
07:37AM  GSKs 2Q17 Earnings: Global Pharmaceuticals Market Realist
Aug-01-17 01:58PM  Innoviva, Inc. -- Moody's assigns B3 CFR to Innoviva; stable outlook Moody's
10:39AM  GlaxoSmithKlines 2Q17 Earnings: HIV Business Market Realist
09:20AM  August PDUFA Dates: Biotech Investors Stay Tuned To A Month Of Plenty Benzinga
09:13AM  How Gilead Sciences Performed in 2Q17 Market Realist
09:10AM  GSKs 2Q17 Earnings: Pharmaceuticals Segment Market Realist
07:41AM  GlaxoSmithKlines 2Q17 Earnings: Business Segments Market Realist
Jul-31-17 05:21PM  Foreign Stock Roundup: GSK, Shell, AstraZeneca Beat on Earnings Zacks
04:32PM  GlaxoSmithKlines 2Q17 Earnings Reveal Growth Market Realist
09:56AM  J&J arthritis drug sirukumab raises safety concerns -FDA staff Reuters
09:46AM  8 Of The Biggest Whistles Ever Blown On Wall Street Benzinga
08:33AM  Former Walmart CIO Named Chief Digital And Technology Officer Of GlaxoSmithKline Forbes
08:06AM  Pharma Stock Roundup: Q2 Earnings Results from Merck, Lilly, Bristol-Myers & More Zacks
Jul-28-17 05:21PM  Data supports safety of Dynavax hepatitis B vaccine -U.S. FDA panel Reuters
12:36PM  GlaxoSmithKline Plc :GSK-US: Earnings Analysis: Q2, 2017 By the Numbers : July 28, 2017 Capital Cube
07:00AM  Gilead's HCV and HIV Drugs Support Wide Moat Morningstar
06:36AM  Dividends a worry at drugmakers Astra, GSK after dramatic week Reuters
06:29AM  Dividends a worry at drugsmakers Astra, GSK after dramatic week Reuters
Jul-27-17 04:27PM  GlaxoSmithKline Capital Inc. -- Moody's changes outlook on GSK's A2 rating to stable from negative; affirms ratings Moody's
02:00PM  Overhaul Drug R&D? Easier Said Than Done Bloomberg
11:27AM  GlaxoSmithKline (GSK) Beats on Q2 Earnings, Lowers Guidance Zacks
01:09AM  [$$] Glaxo Slashes R&D Projects to Focus on Top Prospects The Wall Street Journal
Jul-26-17 09:58PM  Glaxo reports 2Q loss Associated Press
04:38PM  GlaxoSmithKline's new boss streamlines R&D, axes slew of drugs Reuters
12:59PM  GSK gives up on rare diseases as gene therapy gets two customers Reuters
12:49PM  [$$] Love Island adds to attraction of ITV ad hopes Financial Times
11:22AM  [$$] Glaxo Slashes R&D Projects to Focus on Top Prospects The Wall Street Journal
09:46AM  Glaxo Looks Beyond the Lab Bloomberg
09:27AM  Glaxo CFO Says Prioritizing R&D for Product Growth Bloomberg Video
09:12AM  Drugmaker GSK calls for at least two years' Brexit transition Reuters
09:10AM  Glaxo (GSK) Beats Q2 Earnings, Misses Sales Zacks
07:58AM  Drugmaker GSK reviewing its R&D programs under new CEO Associated Press
07:44AM  GlaxoSmithKline on the Street: Analyst Recommendations after 2Q17 Market Realist
07:10AM  GSK Stock Falls on Reduced Guidance
06:13AM  GlaxoSmithKline's new boss streamlines drug research Reuters
Jul-25-17 06:06PM  Unpacking GlaxoSmithKlines 2Q17 Revenue Expectations Market Realist
04:25PM  Inside GlaxoSmithKlines 2Q17 Earnings Estimates Market Realist
11:18AM  Drug Stocks Q2 Earnings Releases on Jul 26: GILD, VRTX, GSK Zacks
09:34AM  ViiV Healthcare Announces Superior Efficacy of Dolutegravir Versus Lopinavir/Ritonavir in Second-line HIV Treatment in Resource-limited Settings PR Newswire
09:03AM  ViiV Healthcare Announces Superior Efficacy of Dolutegravir Versus Lopinavir/Ritonavir in Second-line HIV Treatment in Resource-limited Settings PR Newswire
09:02AM  GlaxoSmithKline Names Former Walmart Exec as New CTO
08:11AM  GSK hires ex-Wal-Mart executive to transform tech operations Reuters
08:08AM  GSK hires ex-Wal-Mart executive to transform tech operations Reuters
07:40AM  Corporate News Blog - GlaxoSmithKline and Innoviva Submits EU Filing for Extended Use of Relvar Ellipta in Patients with Controlled Asthma Accesswire
07:35AM  Analysts Recommendations for Merck in July 2017 Market Realist
07:15AM  GSK hires ex-Wal-Mart executive to transform tech operations Reuters
Jul-24-17 06:05PM  GSK-backed ViiV Healthcare pushing forward in HIV treatments American City Business Journals
04:45PM  Gilead's HIV Drug Matches Glaxo Rival In Late-Stage Trials Investor's Business Daily
09:30AM  The Zacks Analyst Blog Highlights: Alphabet, GlaxoSmithKline, T-Mobile, Northrop Grumman and CSX Zacks
04:00AM  HIV fight advances with new drug cocktails, fresh vaccine hopes Reuters
Jul-21-17 05:01PM  Top Stock Reports for Alphabet, GlaxoSmithKline & T-Mobile Zacks
09:00AM  GSK Submits EU Filing for Extended Use of Relvar Ellipta in Patients with Controlled Asthma on an ICS/LABA Combination Business Wire
Jul-20-17 06:19PM  Emergent Inks Agreement to Acquire Anthrax Drug Raxibacumab Zacks
04:12PM  These Non-Tech Firms Are Making Big Bets On Artificial Intelligence Investor's Business Daily
03:10PM  Emergent BioSolutions acquires GlaxoSmithKline anthrax drug for $96 million American City Business Journals
11:12AM  What Lies in Store for Glaxo (GSK) this Earnings Season? Zacks
Jul-19-17 12:18PM  [$$] GlaxoSmithKline to Sell Its U.K. Horlicks Brand The Wall Street Journal
09:27AM  GSK puts old antibiotics and UK Horlicks business on the block Reuters
09:21AM  [$$] Novartis, Glaxo and Lilly Bigly Back New Biotech
Jul-17-17 09:33PM  3 Value Stocks for Conservative Investors Motley Fool
Jul-15-17 04:00AM  Gilead (GILD) Application for HIV Drug Validated in EU Zacks
Jul-14-17 02:35PM  Gilead (GILD) Application for HIV Drug Validated in EU Zacks
Jul-07-17 04:07PM  GlaxoSmithKlines Performance in 2Q17 Market Realist
08:25AM  Pharma Stock Roundup: MRK's Keytruda MM Combo Studies on Clinical Hold, Bayer to Revise Outlook Zacks
Jul-05-17 04:14PM  Tesla's Stock Is Only Worth This Much: Goldman Investor's Business Daily
12:17PM  Healthcare Repeal Bad For GlaxoSmithKline, Other HIV Treatment Stocks Benzinga
11:01AM  Attention Biotech Investors: Keep Your Date With July PDUFA Action-Days Benzinga
10:20AM  Bank on Gilead Sciences, Inc. (GILD) Stock Getting Its Mojo Back InvestorPlace
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories under the Otrivin, Panadol, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. GlaxoSmithKline plc has a strategic drug discovery collaboration with Exscientia Limited to discover novel and selective small molecules for up to 10 disease-related targets across various therapeutic areas; and a collaboration agreement with Oklahoma Medical Research Foundation for the discovery, development, and commercialization of therapies to prevent organ damage and death caused by acute pancreatitis, lung injury, and trauma conditions. The company was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GLAXOSMITHKLINE PLC10% OwnerOct 24Buy14.0066,500931,0003,220,627Oct 26 05:49 PM